Description:
ChromogenixCoamatic®Antithrombin isa chromogenicassaykitforinvitrodiagnosticdeterminationofantithrombinactivityinhumanplasma.TheuseoffactorXainpreferencetothrombineliminatesinterferencefromheparincofactorIIandthrombininhibitors.ThisFXa-basedantithrombin testkit hasbeenshowntodiscriminatebetterbetweenAT-deficientandnon-AT-deficientindividualsthanathrombin-basedassay[Demersetal1993].Italsogivesaccurateresultsinpatientswhoarereceivingheparintherapy[Bohneretal1994].Simple,accurateandconvenient.AllmethodsarebasedonFXainhibition.Allowsaccuratedeterminationofantithrombininpatientsreceivingheparintherapy.SuperiorreagentstABIlity.Validatedanddocumentedprotocolsforawiderangeofinstruments.Suitableforbothlargeandsmalllaboratories.
Features:
- UseofFXainsteadofthrombineliminatesinterferencefromheparincofactorIIanddirectthrombininhibitors
- HighlysensitiveFXachromogenicsubstrateandsuperiorreagentstability
- Highaccuracyandprecision–CVvalueslessthan5%
- Applicationsavailableforawiderangeofautomatedcoagulationanalyzers,includingtheBCS
- Accuratedeterminationsinpatientsreceivingheparintherapy
- Suitableforbothlargeandsmalllaboratories
KitComposition:
Reagents, Packaging,Storage,Stability
- SubstrateS-2765™, 1vial, 6months, 2-8°C
- BufferwithHeparin, 1vial, 3months, 2-8°C
- FXa, 1vial, 3months, 2-8°C
Determinationsperkit:
- 50(testtube)
- 200(microplate)
- upto130(automated)
MeasurementPrinciple:
| AT+Heparin | ———> | [AT·Heparin] |
| [AT·Heparin]+FXa(excess) | ———> | [AT·Heparin·FXa]+FXa(residual) |
| FXa(residual) | ||
| S-2765™ | ———> | Peptide+pNA |
AT=Antithrombin
Background:
Antithrombinisacirculatingplasmaproteinthatfunctionsasanimportantregulator ofbloodcoagulation.Itinactivatesseveralenzymesofthecoagulationcascade,in particularthrombinandfactorXa.Sincealinkbetweenhereditaryantithrombin deficiencyandthrombosiswasestablishedin1965,therehasbeenincreasingclinical interestinantithrombinandaneedforsimpleandaccuratedetermination.Assays basedonchromogenicpeptidesubstratesarenowavailable,allowingphotometric detectionofantithrombinactivityinplasma.Readmore…
